An open label study to evaluate the effect of first line treatment with Tarceva [erlotinib] in combination with gemcitabine on overall survival and disease progression in patients with locally advanced, unresectable or metastatic pancreatic cancer.
Phase of Trial: Phase IV
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Roche
- 17 Jun 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Apr 2008 New trial record.